{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:46:03Z","timestamp":1791960363570,"version":"4.3.4"},"reference-count":35,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jcim-2024-0425_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The liver is vital for metabolism, detoxification, storage, and secretion. Cholestasis, in which bile flow is hindered, can cause serious harm to the liver. This study examines the potential of ellagic acid to prevent cholestasis in male rats that has been caused by alpha-naphthyl isothiocyanate (ANIT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2024-0425_abs_002\">\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Male rats were divided into four groups for an 8-day study. The control group received 5\u202f% dimethyl sulfoxide (DMSO) orally for eight days and maize oil (1\u202fmL\/kg, orally) 48\u202fh before sacrifice. The ANIT Group received 5\u202f% DMSO orally for 8\u00a0days, the ANIT (100\u202fmg\/kg, orally) administered on the 6th day, 48\u202fh before sacrifice. The low-Dose Ellagic Acid + ANIT Group was given ellagic acid (5\u202fmg\/kg, orally) for eight days, with ANIT (100\u202fmg\/kg, orally) on the 6th day, 48\u202fh prior to sacrifice. The high-Dose Ellagic Acid + ANIT Group received ellagic acid (10\u202fmg\/kg, orally) for eight days, the ANIT (100\u202fmg\/kg, orally) on the 6th\u00a0day, 48\u202fh before sacrifice. Different biochemical and histopathological analyses were conducted to assess the protective effects of ellagic acid on ANIT-induced liver injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2024-0425_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ANIT significantly elevated serum of liver enzymes. It caused severe bile duct inflammation and reduced bile salt export pump (BSEP) and Na+-taurocholate cotransporting polypeptide (NTCP) expression, indicating liver injury. Ellagic\u00a0acid treatment mitigated these changes, improving biochemical parameters and reducing liver damage. ANIT-induced cholestasis results in bile acid accumulation due to decreased BSEP and NTCP expression linked to impaired farnesoid X receptor (FXR) signaling. Ellagic acid restored BSEP and NTCP levels via FXR activation, reducing bile acids and inflammatory markers IL-1\u03b2 and TNF-\u03b1. Ellagic acid also enhanced SIRT1 activity, further improving FXR function and bile acid homeostasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2024-0425_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Ellagic acid exhibits protective effects against cholestasis by enhancing the FXR signaling and\n                      <jats:italic>ntcp<\/jats:italic>\n                      and\u00a0\n                      <jats:italic>bsep<\/jats:italic>\n                      expression with mitigating liver damage and inflammation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jcim-2024-0425","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:10:33Z","timestamp":1739146233000},"page":"296-303","source":"Crossref","is-referenced-by-count":2,"title":["Ellagic acid mitigates alpha-naphthyl isothiocyanate-induced cholestasis in rats via FXR activation and inflammatory pathway modulation"],"prefix":"10.1515","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3094-2126","authenticated-orcid":false,"given":"Hamza","family":"Ahmed Taher","sequence":"first","affiliation":[{"name":"Directorate of Health Diyala, Ministry of Health , Baghdad , Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0552-6469","authenticated-orcid":false,"given":"Munaf Hashim","family":"Zalzala","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology , College of Pharmacy, University of Baghdad , Baghdad , Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"2026101405585248318_j_jcim-2024-0425_ref_001","doi-asserted-by":"crossref","unstructured":"Kareem, VS, Zalzala, MH. Safranal effect against cyclophosphamide-induced liver injury. Iraq J Pharma Sci 2021;30:208\u201313. https:\/\/doi.org\/10.31351\/vol30iss2pp208-213.","DOI":"10.31351\/vol30iss2pp208-213"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_002","doi-asserted-by":"crossref","unstructured":"Ibrahim, MN, Bl\u00e1zquez-Garc\u00eda, R, Lightstone, A, Meng, F, Bhat, M, El Kaffas, A, et al.. Automated fatty liver disease detection in point-of-care ultrasound B-mode images. J Med Imaging 2023;10:034505. https:\/\/doi.org\/10.1117\/1.jmi.10.3.034505.","DOI":"10.1117\/1.JMI.10.3.034505"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_003","doi-asserted-by":"crossref","unstructured":"Nguyen, KD, Sundaram, V, Ayoub, WS. Atypical causes of cholestasis. World J Gastroenterol 2014;20:9418\u201326. https:\/\/doi.org\/10.3748\/wjg.v20.i28.9418.","DOI":"10.3748\/wjg.v20.i28.9418"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_004","doi-asserted-by":"crossref","unstructured":"Li, T, Chiang, JYL. Bile acid-induced liver injury in cholestasis. In: Cellular Injury in Liver Diseases. Cham, Switzerland: Springer International Publishing; 2017:143\u201372 pp.","DOI":"10.1007\/978-3-319-53774-0_7"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_005","doi-asserted-by":"crossref","unstructured":"Sun, L, Cai, J, Gonzalez, FJ. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nat Rev Gastroenterol Hepatol Nat Res 2021;18:335\u201347. https:\/\/doi.org\/10.1038\/s41575-020-00404-2.","DOI":"10.1038\/s41575-020-00404-2"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_006","unstructured":"Stieger, B, Meier, PJ. Bile acid transporters. Clinical Liver Disease 2018;22:331\u201341."},{"key":"2026101405585248318_j_jcim-2024-0425_ref_007","doi-asserted-by":"crossref","unstructured":"Atshan, DA, Zalzala, M. Possible protective effect of papaverine on ANIT induce cholestasis in rat. Iraq J Pharma Sci 2023;32:118\u201326.","DOI":"10.31351\/vol32issSuppl.pp118-126"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_008","doi-asserted-by":"crossref","unstructured":"Wang, W, Wang, S, Liu, Y, Wang, X, Nie, J, Meng, X, et al.. Ellagic acid: a dietary-derived phenolic compound for drug discovery in mild cognitive impairment. Front Aging Neurosci 2022;14:925855. https:\/\/doi.org\/10.3389\/fnagi.2022.925855.","DOI":"10.3389\/fnagi.2022.925855"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_009","doi-asserted-by":"crossref","unstructured":"Gupta, A, Singh, AK, Kumar, R, Jamieson, S, Pandey, AK, Bishayee, A. Neuroprotective potential of ellagic acid: a critical review. Adv Nutr 2021;12:1211\u201338. https:\/\/doi.org\/10.1093\/advances\/nmab007.","DOI":"10.1093\/advances\/nmab007"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_010","doi-asserted-by":"crossref","unstructured":"Zhao, L, Mehmood, A, Soliman, MM, Iftikhar, A, Iftikhar, M, Aboelenin, SM, et al.. Protective effects of ellagic acid against alcoholic liver disease in mice. Front Nutr 2021;8:744520. https:\/\/doi.org\/10.3389\/fnut.2021.744520.","DOI":"10.3389\/fnut.2021.744520"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_011","doi-asserted-by":"crossref","unstructured":"Ceci, C, Graziani, G, Faraoni, I, Cacciotti, I. Strategies to improve ellagic acid bioavailability: from natural or semisynthetic derivatives to nanotechnological approaches based on innovative carriers. Nanotechnology 2020;31:382001. https:\/\/doi.org\/10.1088\/1361-6528\/ab912c.","DOI":"10.1088\/1361-6528\/ab912c"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_012","doi-asserted-by":"crossref","unstructured":"Umesalma, S, Sudhandiran, G. Differential inhibitory effects of the polyphenol ellagic acid on inflammatory mediators NF-\u03baB, iNOS, COX-2, TNF-\u03b1, and IL-6 in 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Basic Clin Pharmacol Toxicol 2010;107:650\u20135. https:\/\/doi.org\/10.1111\/j.1742-7843.2010.00565.x.","DOI":"10.1111\/j.1742-7843.2010.00565.x"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_013","doi-asserted-by":"crossref","unstructured":"Khaleel, RA, Zalzala, MH. Ameliorating effect of oral guggulsterone administration in imiquimod-induced psoriasis in mice. Iraqi J Pharma Sci 2018;27:15\u201323. https:\/\/doi.org\/10.31351\/vol27iss2pp15-23.","DOI":"10.31351\/vol27iss2pp15-23"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_014","doi-asserted-by":"crossref","unstructured":"Yu, L, Liu, X, Yuan, Z, Li, X, Yang, H, Yuan, Z, et al.. SRT1720 alleviates ANIT-induced cholestasis in a mouse model. Front Pharmacol 2017;8:256. https:\/\/doi.org\/10.3389\/fphar.2017.00256.","DOI":"10.3389\/fphar.2017.00256"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_015","doi-asserted-by":"crossref","unstructured":"Gibson-Corley, KN, Olivier, AK, Meyerholz, DK. Principles for valid histopathologic scoring in research. Veterinary Pathol 2013;50:1007\u201315. https:\/\/doi.org\/10.1177\/0300985813485099.","DOI":"10.1177\/0300985813485099"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_016","doi-asserted-by":"crossref","unstructured":"Beuers, U, Trauner, M, Jansen, P, Poupon, R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015;62:S25\u201337. https:\/\/doi.org\/10.1016\/j.jhep.2015.02.023.","DOI":"10.1016\/j.jhep.2015.02.023"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_017","doi-asserted-by":"crossref","unstructured":"Ou, QQ, Qian, XH, Li, DY, Zhang, YX, Pei, XN, Chen, JW, et al.. Yinzhihuang attenuates ANIT-induced intrahepatic cholestasis in rats through upregulation of Mrp2 and Bsep expressions. Pediatr Res 2016;79:589\u201395. https:\/\/doi.org\/10.1038\/pr.2015.252.","DOI":"10.1038\/pr.2015.252"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_018","doi-asserted-by":"crossref","unstructured":"Tanaka, Y, Aleksunes, LM, Cui, YJ, Klaassen, CD. ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling. Toxicol Sci 2009;108:247\u201357. https:\/\/doi.org\/10.1093\/toxsci\/kfp020.","DOI":"10.1093\/toxsci\/kfp020"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_019","doi-asserted-by":"crossref","unstructured":"Ding, LL, Zhang, BF, Dou, W, Yang, L, Zhan, CS, Wang, ZT. Protective effect of Danning tablet on acute livery injury with cholestasis induced by \u03b1-naphthylisothiocyanate in rats. J Ethnopharmacol 2012;140:222\u20139. https:\/\/doi.org\/10.1016\/j.jep.2011.12.047.","DOI":"10.1016\/j.jep.2011.12.047"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_020","doi-asserted-by":"crossref","unstructured":"Newsome, PN, Cramb, R, Davison, SM, Dillon, JF, Foulerton, M, Godfrey, EM, et al.. Guidelines on the management of abnormal liver blood tests. Gut 2018;67:6\u201319. https:\/\/doi.org\/10.1136\/gutjnl-2017-314924.","DOI":"10.1136\/gutjnl-2017-314924"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_021","doi-asserted-by":"crossref","unstructured":"Lu, L. Guidelines for the management of cholestatic liver diseases (2021). J Clin Transl Hepatol 2022;10:757\u201369. https:\/\/doi.org\/10.14218\/jcth.2022.00147.","DOI":"10.14218\/JCTH.2022.00147"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_022","doi-asserted-by":"crossref","unstructured":"Cui, YJ, Aleksunes, LM, Tanaka, Y, Goedken, MJ, Klaassen, CD. Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-Null mice. Toxicol Sci 2009;110:47\u201360. https:\/\/doi.org\/10.1093\/toxsci\/kfp094.","DOI":"10.1093\/toxsci\/kfp094"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_023","doi-asserted-by":"crossref","unstructured":"Pollock, G, Minuk, GY. Diagnostic considerations for cholestatic liver disease. J Gastroenterol Hepatol 2017, 32:1303\u20139. https:\/\/doi.org\/10.1111\/jgh.13738.","DOI":"10.1111\/jgh.13738"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_024","doi-asserted-by":"crossref","unstructured":"Aslan, A, Gok, O, Beyaz, S, A\u011fca, CA, Erman, O, Zerek, A. Ellagic acid prevents kidney injury and oxidative damage via regulation of Nrf-2\/NF-\u03baB signaling in carbon tetrachloride induced rats. Mol Biol Rep 2020;47:7959\u201370. https:\/\/doi.org\/10.1007\/s11033-020-05873-x.","DOI":"10.1007\/s11033-020-05873-x"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_025","doi-asserted-by":"crossref","unstructured":"Jedidi, S, Aloui, F, Selmi, S, Selmi, H, Sammari, H, Ayari, A, et al.. Antioxidant properties of salvia officinalis decoction extract and mechanism of its protective effects on ethanol-induced liver and kidney injuries. J Med Food 2022;25:546\u201356. https:\/\/doi.org\/10.1089\/jmf.2021.0134.","DOI":"10.1089\/jmf.2021.0134"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_026","doi-asserted-by":"crossref","unstructured":"Al-Khfajy, WS, Arif, IS, Al-Sudani, BT Role of fasting mimicking diet in farnesoid x receptor for suppressing epithelial-to-mesenchymal transition, cell cycle progression, and viability of prostate cancer cells. Iraq J Pharma Sci 2023;32:115\u201324, https:\/\/doi.org\/10.31351\/vol32iss1pp115-124.","DOI":"10.31351\/vol32iss1pp115-124"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_027","doi-asserted-by":"crossref","unstructured":"Sinal, CJ, Tohkin, M, Miyata, M, Ward, JM, Lambert, G, Gonzalez, FJ. Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis proliferator-activated receptor (PPAR), retinoic acid re-ceptor (RAR), vitamin D receptor, and thyroid hormone receptor, all of which form heterodimers with a common BAR and to specifically examine its role in BA and lipid. Cell 2000;102:731\u201344. https:\/\/doi.org\/10.1016\/s0092-8674(00)00062-3.","DOI":"10.1016\/S0092-8674(00)00062-3"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_028","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Rodr\u00edguez, JL, Barbier-Torres, L, Fern\u00e1ndez-\u00c1lvarez, S, Guti\u00e9rrez-de Juan, V, Monte, MJ, Halilbasic, E, et al.. SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. Hepatology 2014;59:1972\u201383. https:\/\/doi.org\/10.1002\/hep.26971.","DOI":"10.1002\/hep.26971"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_029","doi-asserted-by":"crossref","unstructured":"Leone, V, D\u2019Angelo, D, Ferraro, A, Pallante, P, Rubio, I, Santoro, M, et al.. A TSH-CREB1-microRNA loop is required for thyroid cell growth. Mol Endocrinol 2011;25:1819\u201330. https:\/\/doi.org\/10.1210\/me.2011-0014.","DOI":"10.1210\/me.2011-0014"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_030","doi-asserted-by":"crossref","unstructured":"Soroka, CJ, Ballatori, N, Boyer, JL. Organic solute transporter, OSTalpha-OSTbeta: its role in bile acid transport and cholestasis. Semin Liver Dis 2010;30:178\u201385. https:\/\/doi.org\/10.1055\/s-0030-1253226.","DOI":"10.1055\/s-0030-1253226"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_031","doi-asserted-by":"crossref","unstructured":"Trauner, M, Boyer, JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003;83:633\u201371. https:\/\/doi.org\/10.1152\/physrev.00027.2002.","DOI":"10.1152\/physrev.00027.2002"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_032","doi-asserted-by":"crossref","unstructured":"Baeeri, M, Mohammadi-Nejad, S, Rahimifard, M, Navaei-Nigjeh, M, Moeini-Nodeh, S, Khorasani, R, et al.. Molecular and biochemical evidence on the protective role of ellagic acid and silybin against oxidative stress-induced cellular aging. Mol Cell Biochem 2018;441:21\u201333. https:\/\/doi.org\/10.1007\/s11010-017-3172-0.","DOI":"10.1007\/s11010-017-3172-0"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_033","doi-asserted-by":"crossref","unstructured":"Chatterjee, A, Chatterjee, S, Das, S, Saha, A, Chattopadhyay, S, Bandyopadhyay, SK. Ellagic acid facilitates indomethacin-induced gastric ulcer healing via COX-2 up-regulation. Acta Biochim Biophys Sin 2012;44:565\u201376. https:\/\/doi.org\/10.1093\/abbs\/gms034.","DOI":"10.1093\/abbs\/gms034"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_034","doi-asserted-by":"crossref","unstructured":"Kathem, SH, Abdulsahib, WK, Zalzala, MH. Berbamine and thymoquinone exert protective effects against immune-mediated liver injury via NF-\u03baB dependent pathway. Front Vet Sci 2022;26:960981.","DOI":"10.3389\/fvets.2022.960981"},{"key":"2026101405585248318_j_jcim-2024-0425_ref_035","doi-asserted-by":"crossref","unstructured":"Atshan, DA, Zalzala, M\u041d. Possible protective effect of papaverine on ANIT induce cholestasis in rat. Iraq J Pharma Sci 2023;32:118\u201326.","DOI":"10.31351\/vol32issSuppl.pp118-126"}],"container-title":["Journal of Complementary and Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2024-0425\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2024-0425\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:00:32Z","timestamp":1791957632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2024-0425\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,11]]},"published-print":{"date-parts":[[2025,6,3]]}},"alternative-id":["10.1515\/jcim-2024-0425"],"URL":"https:\/\/doi.org\/10.1515\/jcim-2024-0425","relation":{},"ISSN":["1553-3840"],"issn-type":[{"value":"1553-3840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}